Lab Publications

(Selected from 63)

O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, , Brautigan DL, Haider S, Jackson M, Narla G. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene. 2020. doi: 10.1038/s41388-019-1012-2.

Knarr M, Kwiatkowski LJ, McAnulty J, Skala S, Arvil S, Drapkin R, A miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. Nature Communications, Nat Commun. 2020 Jun 26;11(1):3231. doi: 10.1038/s41467-020-17030-w.





Belur Nagaraj, Joseph P, Ponting E, Fedorov Y, Singh S, Cole A, Lee W, Yoon E, Baccarini A, Scacheri P, Buckanovich R, Adams DJ, Drapkin R, Brown BD, DiFeo A. A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs. Stem Cell Reports. 2019 Jan 8;12(1):122-134.

Knarr M, Belur Nagaraj A, Kwiatkowski LJ and. miR-181a modulates circadian rhythm in immortalized bone marrow and adipose derived stromal cells and promotes differentiation through the regulation of PER3.  Sci Rep. 2019 Jan 22;9(1):307.


Belur Nagaraj A, Joseph, DiFeo A. Repurposed Drugs Trials for Ovarian Cancer. Cancer J. 2019;25(2):149-152.


Taylor SE, O'Connor C, Wang Z, Shen G, Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S, Zanotti K, Armstrong AJ, Nagel C, Resnick K, Singh S, Jackson MW, Xu W, Haider D, and Narla G. The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis. Cancer Research doi: 10.1158/0008-5472.CAN-19-0218


Parasido E, Avetian G, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, , Narla G, Winter J, Brody JR, Rodriguez O, Albanese C. The sustained induction of c-Myc drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells. Mol Cancer Res. 2019 doi: 10.1158/1541-7786.MCR-19-0191.


Shang S, Yang J, Jazaeri AA, Duval AJ, Tufan T, Lopes Fischer N, Benamar M, Guessous F, Lee I, Campbell RM, Ebert PJ, Abbas T, Landen CN, , Scacheri PC, Adli M. Chemotherapy-induced distal enhancers drive transcriptional program to maintain the chemoresistant state in ovarian cancer. Cancer Res. 2019; doi: 10.1158/0008-5472.CAN-19-0215.

O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, , Brautigan DL, Haider S, Jackson M, Narla G. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene. 2020. doi: 10.1038/s41388-019-1012-2.




Collins GG, Mesiano S, & DiFeo A Effects of Metformin on Cellular Proliferation and Steroid Hormone Receptors in Patient-Derived, Low-Grade Endometrial Cancer Cell Lines. Reprod Sci. 2018:1933719118779734.

Belur Nagaraj A, Joseph P,  Kovalenko O,  Wang QQ,  Xu R, and DiFeo A. Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecol Oncol. 2018, pii: S0090-8258(18)31238


Belur Nagaraj A, Kovalenko O, Avelar R, Joseph P, Brown A, Surti A, Mantilla S, DiFeo A Mitotic Exit dysfunction through the deregulation of APC/C characterizes cisplatin resistant state in epithelial ovarian cancer. Clinical Cancer Research 2018 Apr 13. pii: clincanres.2885.2017. doi: 10.1158/1078-0432.CCR-17-2885. PMID:29653924


Morrow JJBayles IFunnell APWMiller TESaiakhova ALizardo MM,Bartels CFKapteijn MYHung SMendoza ADhillon GChee DRMyers JTAllen FGambarotti MRighi ADiFeo A,Rubin BPHuang AYMeltzer PSHelman LJPicci PVersteeg H, Stamatoyannopolus J, Khanna C, Scacheri PC. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med. 2018 Jan 15. doi: 10.1038/nm.4475.


McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, ...., DiFeo A, Ioannou YA, Ohlmeyer M, Narla G and Galsky MD Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Res. 2018 pii: canres.0123.2017

Noto FK, Adjan Steffey V, Tong M, Ravichandran K, Zhang W, Arey A, McClain CB, Ostertag E, Mazhar S, Sangodkar J, DiFeo A, Crawford J, Narla G, Jamling TY. Sprague Dawley Rag2 null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts. Mol Cancer Ther. 2018, pii: molcanther.0156.2018. doi: 10.1158/1535-7163.MCT-18-0156.


Nagaraj, A. B., et al. "Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment." Oncogene (2017).

Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma'ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548

Saygin C, Wiechert A, Rao VS, Alluri R, Connor E, Thiagarajan PS, Hale JS, Li Y, Chumakova A, Jarrar A, Parker Y, Lindner DJ, Nagaraj AB, Kim JJ, DiFeo A, Abdul-Karim FW, Michener C, Rose PG, DeBernardo R, Mahdi H, McCrae KR, Lin F, Lathia JD, Reizes O.CD55 regulates self-renewal and cisplatin resistance in endometriod tumors J Exp Med. 2017 Sep 4;214(9):2715-2732s


Dimitrova, N., et al. "InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer." Oncogene (2016).

Hudson CD, Savadelis A, Nagaraj AB, Joseph P, Avril S, DiFeo A et al. Altered glutamine metabolism in platinum resistant ovarian cancer. Oncotarget 2016.

Calura E, Paracchini L, Fruscio R, DiFeo A, Ravaggi A, Peronne J, Martini P, Sales G, Beltrame L, Bignotti E, Tognon G, Milani R, Clivio L, Dell'Anna T, Cattoretti G, Katsaros D, Sartori E, Mangioni C, Ardighieri L, D'Incalci M, Marchini S, Romualdi C.  A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment. Ann Oncol. 2016 Aug;27(8):1511-9

Wiechert A, Saygin C, Thiagarajan PS, Rao V, Hale JS, Gupta N, Hitomi M,  Nagaraj AB, DiFeo A, Lathia JD, Reizes O Cisplatin induces stemness in ovarian cancer. Oncotarget. 2016;7(21):30511-22. doi: 10.18632/oncotarget.8852

Petrillo M, Zannoni G, Beltrame L, Martinelli E, DiFeo A, Paracchini L, Craparotta I, Mannarino L, Vizzielli G, Scambia G, D'Incalci M, Romualdi C, Marchini S Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neo-adjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Ann Oncol. 2016 Jan 17. pii: mdw007

Contact Us: 

(734) 936-5687

Analisa DiFeo (Principal Investigator):

Michele Cusato (Lab Manager):

Visit Us:

University of Michigan

Department of Pathology

1600 Huron Parkway

NCRC B520-3408

Ann Arbor, MI 48109-2800

Follow us on Twitter!

  • Twitter